Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Fiche publication
Date publication
juillet 2005
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Pr BOUCHE Olivier, Pr CONROY Thierry
Tous les auteurs :
Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L
Lien Pubmed
Résumé
Systemic adjuvant chemotherapy can improve overall survival and reduce the incidence of distant metastases for patients with advanced colon cancer. This study aimed to investigate whether regional chemotherapy (given by intraperitoneal or intraportal methods) combined with systemic chemotherapy was more effective than was systemic chemotherapy alone in terms of survival and recurrence for patients with stage II-III colorectal cancer. The study also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole.
Mots clés
Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Chemotherapy, Adjuvant, Chemotherapy, Cancer, Regional Perfusion, Colorectal Neoplasms, drug therapy, Combined Modality Therapy, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Humans, Leucovorin, administration & dosage, Levamisole, administration & dosage, Male, Middle Aged, Survival Analysis
Référence
Lancet Oncol.. 2005 Jul;6(7):459-68